Takeda Pharmaceutical
TSE:4502 Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
WA
Consensus Narrative from 17 Analysts
EU And Japan Approvals For FRUZAQLA And ADYZNMA Will Strengthen Market Position
Key Takeaways Anticipated efficiency gains and strategic expansions are expected to boost profit margins and revenue through new product launches and market share growth. The Growth & Launch product portfolio is driving significant revenue, supported by robust full-year performance and favorable foreign exchange trends.
View narrativeJP¥4.78k
FV
11.7% undervalued intrinsic discount0.65%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
23 days ago author updated this narrative